Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
8-K
Departure of Directors or Certain Officers
22 Apr 24
8-K
Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
7 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
S-8
Registration of securities for employees
31 Jan 24
8-K
Departure of Directors or Certain Officers
30 Jan 24
S-8
Registration of securities for employees
17 Jan 24
8-K
Departure of Directors or Certain Officers
5 Jan 24
S-3ASR
Automatic shelf registration
2 Jan 24
10-Q
2023 Q3
Quarterly report
7 Nov 23
EFFECT
Notice of effectiveness
1 Nov 23
CORRESP
Correspondence with SEC
27 Oct 23
UPLOAD
Letter from SEC
27 Oct 23
S-3
Shelf registration
20 Oct 23
D
$59.99 mm in equity / options / securities to be acquired, sold $59.99 mm, 14 investors
4 Oct 23
8-K
Entry into a Material Definitive Agreement
29 Sep 23
424B5
Prospectus supplement for primary offering
29 Sep 23
FWP
Free writing prospectus
28 Sep 23
FWP
Free writing prospectus
28 Sep 23
S-3MEF
Registration of additional securities for an S-3
27 Sep 23
424B5
Prospectus supplement for primary offering
27 Sep 23
8-K
Termination of a Material Definitive Agreement
27 Sep 23
8-K
Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from
26 Sep 23
8-K
Departure of Directors or Certain Officers
16 Aug 23
S-8
Registration of securities for employees
8 Aug 23
10-Q
2023 Q2
Quarterly report
8 Aug 23
8-K
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
8 Aug 23
EFFECT
Notice of effectiveness
3 Aug 23
CORRESP
Correspondence with SEC
31 Jul 23
S-1/A
IPO registration (amended)
28 Jul 23
UPLOAD
Letter from SEC
28 Jul 23
S-1
IPO registration
21 Jul 23
8-K
Regulation FD Disclosure
10 Jul 23
424B5
Prospectus supplement for primary offering
2 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
26 May 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results
9 May 23
8-K
Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome
3 May 23
ARS
2022 FY
Annual report to shareholders
20 Apr 23
Latest ownership filings
4
Kristen Yen
3 Apr 24
4
James H Mackaness
3 Apr 24
4
Patricia C Hirano
3 Apr 24
4
Bhatnagar Anish
3 Apr 24
SC 13G/A
Nantahala Capital Management, LLC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
13 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
4
Kristen Yen
29 Jan 24
4
Patricia C Hirano
29 Jan 24
4
Bhatnagar Anish
29 Jan 24
4
ERNEST MARIO
10 Jan 24
4
Kristen Yen
8 Jan 24
4
James H Mackaness
8 Jan 24
4
Patricia C Hirano
8 Jan 24
4
Bhatnagar Anish
8 Jan 24
4
Patricia C Hirano
15 Dec 23
4
Kristen Yen
14 Dec 23
144
Notice of proposed sale of securities
14 Dec 23
4
Bhatnagar Anish
13 Dec 23
4
James H Mackaness
13 Dec 23
4
Bhatnagar Anish
13 Dec 23
4
James H Mackaness
13 Dec 23
144
Notice of proposed sale of securities
13 Dec 23
144
Notice of proposed sale of securities
13 Dec 23
144
Notice of proposed sale of securities
12 Dec 23
144
Notice of proposed sale of securities
11 Dec 23
144
Notice of proposed sale of securities
11 Dec 23
4
ERNEST MARIO
4 Dec 23
4
Kristen Yen
4 Dec 23
4
James H Mackaness
4 Dec 23
4
Patricia C Hirano
4 Dec 23
4
Bhatnagar Anish
4 Dec 23
4
Kristen Yen
30 Nov 23
4
James H Mackaness
30 Nov 23
4
Patricia C Hirano
30 Nov 23
4
Bhatnagar Anish
30 Nov 23
SC 13D/A
PERCEPTIVE ADVISORS LLC
23 Oct 23
SC 13D/A
Carlyle Group Inc.
16 Oct 23
SC 13G
ADAGE CAPITAL PARTNERS GP, L.L.C.
12 Oct 23